VLA1553
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus Infection
Conditions
Chikungunya Virus Infection
Trial Timeline
Apr 2, 2021 → May 1, 2031
NCT ID
NCT04838444About VLA1553
VLA1553 is a phase 3 stage product being developed by Valneva SE for Chikungunya Virus Infection. The current trial status is active. This product is registered under clinical trial identifier NCT04838444. Target conditions include Chikungunya Virus Infection.
What happened to similar drugs?
0 of 10 similar drugs in Chikungunya Virus Infection were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06028841 | Phase 3 | Withdrawn |
| NCT04838444 | Phase 3 | Active |
| NCT03382964 | Phase 1 | Completed |
Competing Products
20 competing products in Chikungunya Virus Infection